| 1 | 1 | | IV |
|---|
| 2 | 2 | | 119THCONGRESS |
|---|
| 3 | 3 | | 1 |
|---|
| 4 | 4 | | STSESSION H. RES. 360 |
|---|
| 5 | 5 | | Expressing support for the designation of the last Tuesday of April each |
|---|
| 6 | 6 | | year as ‘‘APOL1–Mediated Kidney Disease (AMKD) Awareness Day’’. |
|---|
| 7 | 7 | | IN THE HOUSE OF REPRESENTATIVES |
|---|
| 8 | 8 | | APRIL29, 2025 |
|---|
| 9 | 9 | | Ms. P |
|---|
| 10 | 10 | | LASKETT(for herself, Ms. DELBENE, Ms. BROWNLEY, Mr. DAVISof |
|---|
| 11 | 11 | | North Carolina, Mrs. C |
|---|
| 12 | 12 | | HERFILUS-MCCORMICK, Ms. SEWELL, Ms. |
|---|
| 13 | 13 | | S |
|---|
| 14 | 14 | | TANSBURY, Ms. ADAMS, Ms. CLARKEof New York, Mr. DAVISof Illi- |
|---|
| 15 | 15 | | nois, Ms. W |
|---|
| 16 | 16 | | ILSONof Florida, and Mr. JOHNSONof Georgia) submitted |
|---|
| 17 | 17 | | the following resolution; which was referred to the Committee on Energy |
|---|
| 18 | 18 | | and Commerce |
|---|
| 19 | 19 | | RESOLUTION |
|---|
| 20 | 20 | | Expressing support for the designation of the last Tuesday |
|---|
| 21 | 21 | | of April each year as ‘‘APOL1–Mediated Kidney Disease |
|---|
| 22 | 22 | | (AMKD) Awareness Day’’. |
|---|
| 23 | 23 | | Whereas kidney disease affects an estimated 35,500,000 |
|---|
| 24 | 24 | | Americans, and more than 550,000 are on dialysis; |
|---|
| 25 | 25 | | Whereas Black individuals with kidney disease are more likely |
|---|
| 26 | 26 | | to develop kidney failure than any other racial group; |
|---|
| 27 | 27 | | Whereas the health disparities in kidney failure are |
|---|
| 28 | 28 | | unsustainable, with Black people making up 13 percent |
|---|
| 29 | 29 | | of the United States population but accounting for 30 |
|---|
| 30 | 30 | | percent of those with kidney failure; |
|---|
| 31 | 31 | | VerDate Sep 11 2014 01:13 Apr 30, 2025 Jkt 059200 PO 00000 Frm 00001 Fmt 6652 Sfmt 6300 E:\BILLS\HR360.IH HR360 |
|---|
| 32 | 32 | | kjohnson on DSK7ZCZBW3PROD with $$_JOB 2 |
|---|
| 33 | 33 | | •HRES 360 IH |
|---|
| 34 | 34 | | Whereas kidney failure places enormous physical, emotional, |
|---|
| 35 | 35 | | and financial burdens on individuals and costs the Medi- |
|---|
| 36 | 36 | | care Program over $45,000,000,000 annually; |
|---|
| 37 | 37 | | Whereas there are genetic factors that can increase an indi- |
|---|
| 38 | 38 | | vidual’s risk for kidney disease; |
|---|
| 39 | 39 | | Whereas one such genetic factor is having variants |
|---|
| 40 | 40 | | (mutations) in the apolipoprotein L1 (APOL1) gene; |
|---|
| 41 | 41 | | Whereas people are more likely to have APOL1 gene variants |
|---|
| 42 | 42 | | if they are from Western or Central Africa or have an |
|---|
| 43 | 43 | | ancestor who came from these regions; |
|---|
| 44 | 44 | | Whereas these variants can increase susceptibility for |
|---|
| 45 | 45 | | APOL1-mediated kidney disease (AMKD), a rapidly pro- |
|---|
| 46 | 46 | | gressive form of kidney disease that can lead to kidney |
|---|
| 47 | 47 | | failure; |
|---|
| 48 | 48 | | Whereas, it is estimated that if a patient has variants in both |
|---|
| 49 | 49 | | copies of the APOL1 gene, there is a 1 in 5 chance they |
|---|
| 50 | 50 | | will go on to develop kidney disease, and an estimated 13 |
|---|
| 51 | 51 | | percent of Black Americans have variants in both copies |
|---|
| 52 | 52 | | of the APOL1 gene; |
|---|
| 53 | 53 | | Whereas a person with AMKD may not have any symptoms |
|---|
| 54 | 54 | | of kidney disease until their kidneys are close to failing; |
|---|
| 55 | 55 | | Whereas genetic testing can reveal an individual’s risk for |
|---|
| 56 | 56 | | AMKD, empowering them to take the steps necessary to |
|---|
| 57 | 57 | | protect their kidney health before it is too late; |
|---|
| 58 | 58 | | Whereas individuals who are found to have APOL1 genetic |
|---|
| 59 | 59 | | variants can reduce their risk for kidney failure by meet- |
|---|
| 60 | 60 | | ing with their doctor regularly, eating a healthy diet, tak- |
|---|
| 61 | 61 | | ing all medications as prescribed, exercising for at least |
|---|
| 62 | 62 | | 30 minutes a day, and not smoking or using tobacco; |
|---|
| 63 | 63 | | VerDate Sep 11 2014 01:13 Apr 30, 2025 Jkt 059200 PO 00000 Frm 00002 Fmt 6652 Sfmt 6300 E:\BILLS\HR360.IH HR360 |
|---|
| 64 | 64 | | kjohnson on DSK7ZCZBW3PROD with $$_JOB 3 |
|---|
| 65 | 65 | | •HRES 360 IH |
|---|
| 66 | 66 | | Whereas additional awareness and research of APOL1 ge- |
|---|
| 67 | 67 | | netic mutations are needed to improve understanding of |
|---|
| 68 | 68 | | the kidney disease disparities in this population; |
|---|
| 69 | 69 | | Whereas there are currently no Food and Drug Administra- |
|---|
| 70 | 70 | | tion-approved treatments available for APOL1-mediated |
|---|
| 71 | 71 | | kidney disease, but ongoing research and clinical trials |
|---|
| 72 | 72 | | could provide an opportunity for researchers to develop |
|---|
| 73 | 73 | | and test safe treatments for APOL1-mediated kidney dis- |
|---|
| 74 | 74 | | ease; and |
|---|
| 75 | 75 | | Whereas the House of Representatives can raise public |
|---|
| 76 | 76 | | awareness of APOL1-mediated kidney disease: Now, |
|---|
| 77 | 77 | | therefore, be it |
|---|
| 78 | 78 | | Resolved, That the House of Representatives— 1 |
|---|
| 79 | 79 | | (1) expresses support for the designation of 2 |
|---|
| 80 | 80 | | ‘‘APOL1-Mediated Kidney Disease (AMKD) Aware-3 |
|---|
| 81 | 81 | | ness Day’’; 4 |
|---|
| 82 | 82 | | (2) encourages each person of the United 5 |
|---|
| 83 | 83 | | States to become better informed about and aware 6 |
|---|
| 84 | 84 | | of kidney disease and APOL1-mediated kidney dis-7 |
|---|
| 85 | 85 | | ease; and 8 |
|---|
| 86 | 86 | | (3) encourages people from or with ancestry 9 |
|---|
| 87 | 87 | | from Western and Central Africa to consider genetic 10 |
|---|
| 88 | 88 | | testing for APOL1 gene mutations. 11 |
|---|
| 89 | 89 | | Æ |
|---|
| 90 | 90 | | VerDate Sep 11 2014 01:13 Apr 30, 2025 Jkt 059200 PO 00000 Frm 00003 Fmt 6652 Sfmt 6301 E:\BILLS\HR360.IH HR360 |
|---|
| 91 | 91 | | kjohnson on DSK7ZCZBW3PROD with $$_JOB |
|---|